Cantor Fitzgerald Reiterates Overweight Rating on Aquestive Therapeutics (AQST)

September 10, 2026 9:31 AM

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $11.00 price target on Aquestive Therapeutics (NASDAQ: AQST).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found